THE PLACE OF INHIBITORS OF SGLT-2 AND GLP-1 RECEPTOR AGONIST IN THE PREVENTION AND TREATMENT OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES

Рахимова Г.Н, Ахроров К.У

Марказий Осиё эндокринологик журнали · 2022-yil

Annotatsiya

According to international standards for the management and treatment of patients with type 2 diabetes mellitus, patients with a reduced glomerular filtration rate (GFR) below 60 ml / min / 1.73 m2, albuminuria, or both in the last 3 months, are diagnosed with chronic kidney disease (CKD) [11]. Chronic kidney disease in type 2 diabetes is not only dangerous for the development of end-stage complications of the kidneys, such as dialysis or transplantation, but also causes a high mortality rate from cardiovascular complications compared with patients without chronic kidney disease and type 2 diabetes [7]. The goal of modern diabetology is to reduce albuminuria and prevent the progression of a decrease in GFR.In our article, we will review and summarize information on the safety and efficacy of using a combination of an SGLT-2 inhibitor and an agonist of GLP-1 receptors, as well as the introduction of this combination into the clinical practice of an endocrinologist in the management of patients with diabetes mellitus and chronic kidney disease.

Maqola ma’lumotlari
MualliflarРахимова Г.Н, Ахроров К.У
JurnalМарказий Осиё эндокринологик журнали
Nashr sanasi2022-08-26
Jild2
Son1
TilRus

Kalit so‘zlar

Агонисты рецептора ГПП-1; ингибиторы НГКТ-2; инфаркт; скорость клубочковой фильтрации; смертность; сахарный диабет 2 типа; хроническая болезнь почек, GO’P-1 retseptorlari agonistlari; NGKT-2 ingibitorlari; yurak xuruji; koptokchalar filtratsiya tezligi; o'lim darajasi; 2-tur qandli diabet; surunkali buyrak kasalligi, GLP-1 receptor agonists; SGLT-2 inhibitors; heart attack; glomerular filtration rate; mortality; type 2 diabetes mellitus; chronic kidney disease

Ilmiy soha

Марказий Осиё эндокринологик журнали jurnalidan boshqa maqolalar

Марказий Осиё эндокринологик журнали — barcha maqolalar